REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug…
Amgen obesity drug MariTide led to high discontinuation rates in trial
CHICAGO — Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects…